

ENDO PHARMACEUTICALS HOLDINGS INC

Form 10-Q

August 14, 2002

Table of Contents

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, 2002

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from ___ to ___.

Commission file number: 39040

ENDO PHARMACEUTICALS HOLDINGS INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or other jurisdiction of (I.R.S.
Employer incorporation or organization)
Identification Number)

13-4022871

100 Painters Drive
Chadds Ford, Pennsylvania 19317
(Address of Principal Executive Offices)

(610) 558-9800
(Registrant's Telephone Number, Including Area Code)

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

The aggregate number of shares of the Registrant's common stock outstanding as of August 14, 2002 was 102,064,450.

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Overview

Three Months Ended June 30, 2002 Compared to the Three Months Ended June 30, 2001

Six Months Ended June 30, 2002 Compared to the Six Months Ended June 30, 2001

Liquidity and Capital Resources

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

General

Item 2. Changes in Securities and Use of Proceeds.

Item 3. Defaults Upon Senior Securities.

Item 4. Submission of Matters to a Vote of Security Holders.

Item 5. Other Information.

Item 6. Exhibits and Reports on Form 8-K.

SIGNATURES

Exhibit Index

EX-11: STATEMENT RE: COMPU. OF PER SHARE EARNINGS

EX-99.1: CERTIFICATE OF CHIEF EXECUTIVE OFFICER

EX-99.2: CERTIFICATE OF CHIEF FINANCIAL OFFICER

Table of Contents

ENDO PHARMACEUTICALS HOLDINGS INC.

**REPORT ON FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2002**

TABLE OF CONTENTS

Page

PART I. FINANCIAL INFORMATION

Item 1.	
Financial	
Statements	
Consolidated	
Balance Sheets	
(Unaudited)	
June 30, 2002	
and	
December 31,	
2001 5	
Consolidated	
Statements of	
Operations	
(Unaudited)	
Three Months	
and Six	
Months Ended	
June 30, 2002	
and	
2001 6	
Consolidated	
Statements of	
Cash Flows	
(Unaudited)	
Six Months	
Ended June 30,	
2002 and	
2001 7	
Notes to	
Consolidated	
Financial	
Statements	
(Unaudited) 8	Item 2.
Management's	
Discussion and	
Analysis of	
Financial	
Condition and	
Results of	
Operations 14	
Overview 14	
Critical	
Accounting	
Policies 14	
Results of	
Operations 15	
Goodwill and	
Other	

Intangibles15
Compensation
Related to
Stock
Options16
Other
Events17
Net
Sales18
Three Months
Ended June 30,
2002
Compared to
the Three
Months Ended
June 30,
2001 18
Six Months
Ended June 30,
2002
Compared to
the Six Months
Ended June 30,
2001 19
Liquidity and
Capital
Resources 21 Item 3.
Quantitative
and Qualitative
Disclosures
about Market
Risk 21

Table of Contents

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	23
Item 2.		
Changes in Securities and Use of Proceeds	24	Item 3.
Defaults Upon Senior Securities	24	Item 4.
Submission of Matters to a Vote of Security Holders	25	Item 5.
Other Information	25	Item 6.
Exhibits and Reports on Form 8-K	26	

Table of Contents

Forward Looking Statements

We have made forward-looking statements in this document within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including estimates of future net sales and consolidated EBITDA contained in the section titled Management's Discussion and Analysis of Financial Condition and Results of Operations, are subject to risks and uncertainties. Forward-looking statements include the information concerning our possible or assumed results of operations. Also, statements including words such as believes, expects, anticipates, intends, estimates, or similar expressions are forward-looking statements. We have based these forward-looking statements on our current expectations and projections about the growth of our business, our financial performance and the development of our industry. Because these statements reflect our current views concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described in Management's Discussion and Analysis of Financial Condition and Results of Operations, Business and elsewhere in this Report could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this Report. Important factors that could cause our actual results to differ materially from the expectations reflected in the forward-looking statements in this Report include, among others:

- our ability to successfully develop, commercialize and market new products;
- results of clinical trials on new products;
- competition for the business of our branded and generic products, and in connection with our acquisition of rights to intellectual property assets;
- market acceptance of our future products;
- government regulation of the pharmaceutical industry;
- our dependence on a small number of products;
- our dependence on outside manufacturers for the manufacture of our products;
- our dependence on third parties to supply raw materials and to provide services for the core aspects of our business;
- new regulatory action or lawsuits relating to the use of narcotics in most of our core products;
- our exposure to product liability claims and product recalls and the possibility that we may not be able to adequately insure ourselves;
- our ability to protect our proprietary technology;
- our ability to successfully implement our acquisition strategy;
- the availability of controlled substances that constitute the active ingredients of some of our products and products in development;
- the availability of third-party reimbursement for our products; and
- our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of our total net sales.

We do not undertake any obligation to update our forward-looking statements after the date of this Report for any reason, even if new information becomes available or other events occur in the future.

Table of Contents**PART I****FINANCIAL INFORMATION****Item 1. Financial Statements**

ENDO PHARMACEUTICALS HOLDINGS INC.
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share data)

	<u>June 30,</u>	<u>December</u>
	<u>2002</u>	<u>31,</u>
		<u>2001</u>
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$151,835	\$95,357
Accounts receivable, net	113,862	85,329
Inventories	29,061	27,766
Prepaid expenses	3,198	5,527
Deferred income taxes	36,286	26,946
<hr/>		
<hr/>		
Total current assets	334,242	240,925
<hr/>		
<hr/>		
PROPERTY AND EQUIPMENT, Net	9,590	9,883
GOODWILL	181,079	182,318
OTHER INTANGIBLES, Net	12,125	12,495
DEFERRED INCOME TAXES	17,167	23,420
RESTRICTED CASH	150	150
OTHER ASSETS		

1,764 1,804

TOTAL ASSETS
\$556,117 \$470,995

**LIABILITIES AND
STOCKHOLDERS EQUITY**

CURRENT LIABILITIES:

Accounts payable
\$35,855 \$30,705
Accrued expenses
91,946 50,176
Income taxes payable
17,620 3,526
Current portion of long-term debt
94,707 91,259

Total current liabilities
240,128 175,666

OTHER LIABILITIES
217 207

COMMITMENTS AND
CONTINGENCIES

STOCKHOLDERS EQUITY

Preferred Stock, \$.01 par value;
40,000,000 shares authorized; none
issued Common Stock, \$.01 par
value; 175,000,000 shares
authorized; 102,064,450 and
102,063,950 issued and outstanding
at June 30, 2002 and December 31,
2001, respectively
1,021 1,021
Additional paid-in capital

512,590	519,316
Accumulated deficit	
(197,839)	(225,215)

Total Stockholders	Equity
315,772	295,122

TOTAL LIABILITIES AND	
STOCKHOLDERS	EQUITY
\$556,117	\$470,995

See Notes to Consolidated Financial Statements

Table of Contents

**ENDO PHARMACEUTICALS HOLDINGS INC.
 CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
 (In thousands, except per share data)**

	Three Months Ended June 30,		Six Months Ended June 30,	
	2002	2001	2002	2001
NET SALES	\$ 107,902	\$ 67,857	\$ 174,928	\$ 107,239
COST OF SALES				
27,805 21,032 46,696 33,681				
<hr/>				
<hr/>				
<hr/>				
<hr/>				
GROSS PROFIT				
80,097 46,825 128,232 73,558				
<hr/>				
<hr/>				
<hr/>				
<hr/>				
<hr/>				
COSTS AND EXPENSES:				
Selling, general and administrative				
27,562 19,453 51,145 35,343				
Research and development				
15,142 8,336 28,538 17,510				
Depreciation and amortization				
691 12,377 1,476 24,776				
<hr/>				
<hr/>				
<hr/>				
<hr/>				
<hr/>				
OPERATING INCOME (LOSS)				

36,702 6,659 47,073 (4,071)

INTEREST EXPENSE, Net of interest income of \$341, \$726, \$648
and \$1,815, respectively
1,649 2,903 3,271 6,443

INCOME (LOSS) BEFORE INCOME TAX
35,053 3,756 43,802 (10,514)
INCOME TAX
13,052 1,025 16,425 993

NET INCOME (LOSS)
\$22,001 \$2,731 \$27,377 \$(11,507)

NET INCOME (LOSS) PER SHARE:

Basic
\$.22 \$.03 \$.27 \$(.13)
Diluted
\$.22 \$.03 \$.27 \$(.13)

NET INCOME PRO FORMA TO EXCLUDE AMORTIZATION
OF GOODWILL AND WORKFORCE-IN-PLACE:
\$22,001 \$9,554 \$27,377 \$7,982

NET INCOME PER SHARE PRO FORMA TO EXCLUDE
AMORTIZATION OF GOODWILL AND
WORKFORCE-IN-PLACE:

Basic
\$.22 \$.11 \$.27 \$.09

Diluted
\$.22 \$.11 \$.27 \$.09

WEIGHTED AVERAGE SHARES:

Basic
102,064 89,139 102,064 89,139

Diluted
102,271 89,213 102,276 89,139

See Notes to Consolidated Financial Statements.

Table of Contents

ENDO PHARMACEUTICALS HOLDINGS INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)

	Six Months Ended June 30,	
	2002	2001
OPERATING ACTIVITIES:		
Net Income (Loss)	\$27,377	\$(11,507)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation and amortization	1,476	24,776
Amortization of deferred financing costs	191	855
Accretion of promissory notes	3,448	2,395
Deferred income taxes	(1,847)	15
Changes in assets and liabilities which provided (used) cash:		
Accounts receivable	(28,533)	7,228
Inventories	(1,295)	6,308
Other assets	2,190	(2,669)
Accounts payable	5,150	1,823
Accrued expenses	41,770	868
Income taxes payable	14,094	(1,541)
Other liabilities	10	10,791
<hr style="border: 0.5px solid black;"/>		
<hr style="border: 0.5px solid black;"/>		
Net cash provided by operating activities	64,031	39,342
INVESTING ACTIVITIES:		
Purchase of property and equipment	(827)	(2,000)

Net cash used in investing activities
(827) (2,000)

FINANCING ACTIVITIES:

Repayments of long-term debt
(29,511)
Exercise of Endo Pharmaceuticals
Holdings Inc. stock options
4
Repurchase of Class A Transferable
and Class B Non-Transferable
Warrants
(6,730)

Net cash used in financing activities
(6,726) (29,511)

NET INCREASE IN CASH AND
CASH EQUIVALENTS
56,478 7,831
CASH AND CASH
EQUIVALENTS, BEGINNING OF
PERIOD
95,357 59,196

CASH AND CASH
EQUIVALENTS, END OF
PERIOD
\$151,835 \$67,027

SUPPLEMENTAL
INFORMATION:

Interest Paid
\$134 \$4,958
Income Taxes Paid
\$4,180 \$2,786

See Notes to Consolidated Financial Statements.

Table of Contents

**ENDO PHARMACEUTICALS HOLDINGS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
FOR THE SIX MONTHS ENDED JUNE 30, 2002**

1. CONSOLIDATED FINANCIAL STATEMENTS

In the opinion of management, the accompanying condensed consolidated financial statements of Endo Pharmaceuticals Holdings Inc. (the Company or we) and its subsidiaries, which are unaudited, include all normal and recurring adjustments necessary to present fairly the Company's financial position as of June 30, 2002 and the results of operations and cash flows for the periods presented. The accompanying consolidated balance sheet as of December 31, 2001 is derived from the Company's audited financial statements. Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted as promulgated by Accounting Principles Board Opinion No. 28 and Rule 10.01 of Regulation S-X under the Securities Act of 1933. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto as of and for the year ended December 31, 2001 contained in the Company's Annual Report on Form 10-K. Certain reclassifications have been made to the prior period's financial statements to conform with the classifications used in 2002.

2. RECENT ACCOUNTING PRONOUNCEMENTS

In June 1998, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 133, Accounting for Derivative Instruments and Hedging Activities, which was effective for all fiscal years beginning after June 15, 2000. SFAS No. 133, as amended by SFAS No. 137 and SFAS No. 138, establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts and for hedging activities. All derivatives, whether designated in hedging relationships or not, are required to be recorded on the balance sheet at fair value. If the derivative is designated in a fair value hedge, the changes in the fair value of the derivative and the hedged item are recognized in earnings. If the derivative is designated as a cash flow hedge, changes in the fair value of the derivative are recorded in other comprehensive income (OCI) and are recognized in the income statement when the hedged item affects earnings. SFAS No. 133 defines new requirements for designation and documentation of hedging relationships as well as ongoing effectiveness assessments in order to use hedge accounting. A derivative that does not qualify as a hedge is marked to fair value through earnings.

At January 1, 2001, we recorded \$228,000 as an accumulated transition adjustment as a reduction to earnings.

In December 1999, the Securities and Exchange Commission (the SEC) issued Staff Accounting Bulletin No. 101, entitled Revenue Recognition in Financial Statements, as amended, effective as of October 1, 2000, which summarizes the SEC's views in applying generally accepted accounting principles to revenue recognition. The adoption of this guideline had no effect on our financial statements.

In March 2000, the FASB issued Financial Accounting Series Interpretation No. 44 entitled Accounting for Certain Transactions Involving Stock Compensation, which provides clarification to Accounting Principles Board Opinion No. 25 (APB No. 25), Accounting for Stock Issued to Employees. The adoption of this interpretation had no effect on our financial statements.

In June 2001, the FASB, issued SFAS No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other Intangible Assets. SFAS No. 141 was effective for all business combinations completed after June 30, 2001. SFAS No. 142 is effective for fiscal years beginning after December 15, 2001. SFAS No. 141 requires that all business combinations be accounted for under the purchase method only and that certain acquired intangible assets in a business combination be recognized as assets apart from goodwill. SFAS No. 142 establishes revised reporting requirements for goodwill and other intangible assets. See note 3 to the consolidated financial statements.

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 10-Q

The pro forma effect of the adoption of SFAS No. 141 and SFAS No. 142 is as follows:

	(Unaudited) Three Months Ended June 30,		(Unaudited) Six Months Ended June 30,	
	2002	2001	2002	2001
	(in thousands, except per share data)			
Reported net income (loss)	\$ 22,001	\$ 2,731	\$ 27,377	\$(11,507)
Add back: Goodwill amortization				
10,225	20,450			
Add back: Amortization of workforce-in-place				
1,487	2,974			
Less: Pro forma income tax				
(4,889)	(3,935)			

Adjusted net income
 \$22,001 \$9,554 \$27,377 \$7,982

Basic earnings (loss) per share:

Reported net income (loss)
 \$.22 \$.03 \$.27 \$(.13)
 Add back: Goodwill amortization
 .11 .23

Table of Contents

(Unaudited) Three Months Ended June 30,		(Unaudited) Six Months Ended June 30,	
2002	2001	2002	2001

(in thousands, except per share data)

Add back: Amortization of
workforce-in-place

.02 .03

Less: Pro forma income tax

(.05) (.04)

Adjusted net income

\$.22 \$.11 \$.27 \$.09

Diluted earnings (loss) per share:

Reported net income (loss)

\$.22 \$.03 \$.27 \$(.13)

Add back: Goodwill amortization

.11 .23

Add back: Amortization of
workforce-in-place

.02 .03

Less: Pro forma income tax

(.05) (.04)

Adjusted net income
 \$.22 \$.11 \$.27 \$.09

Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2001 is as follows (in thousands):

2002	\$ 741
2003	741
2004	741
2005	741
2006	741

4. COMPENSATION RELATED TO STOCK OPTIONS

Endo Pharma LLC 1997 Executive and Employee Stock Option Plans

On November 25, 1997, the Company established the 1997 Employee Stock Option Plan and the 1997 Executive Stock Option Plan (collectively, the 1997 Stock Option Plans). Pursuant to the recapitalization of the Company which took place on July 17, 2000 in connection with our acquisition of Algos, the 1997 Stock Option Plans were amended and restated. The Endo Pharma LLC Amended and Restated 1997 Employee Stock Option Plan and the Endo Pharma LLC Amended and Restated 1997 Executive Stock Option Plan (collectively, the Endo Pharma LLC 1997 Stock Option Plans) reserve an aggregate of 25,615,339 shares of Common Stock of the Company held by Endo Pharma LLC for issuance. Stock options granted under the Endo Pharma LLC 1997 Stock Option Plans expire no later than December 31, 2012 unless an initial public offering of the Company Common Stock held by Endo Pharma LLC occurs, in which case the stock options granted will expire on August 26, 2007. The effect of the Recapitalization has been reflected in the accompanying financial statements. Subsequent to the July 17, 2000 acquisition of Algos, the exercise of stock options pursuant to the Endo Pharma LLC 1997 Stock Option Plans does not result in the issuance of additional shares in the Company.

The Class C stock options vest in four discrete tranches contingent upon (i) the Common Stock of the Company exceeding a defined closing price threshold for ninety consecutive trading days, (ii) the closing price of the Common Stock of the Company on the last trading day of such ninety consecutive trading day period being greater than or equal to 85% of the defined closing price and (iii) the holder being a director, officer or employee of the Company or any of its subsidiaries on such date. The defined closing price thresholds are as follows:

Option Class	MorphiDex® is Approved On or Prior to December 31, 2002	MorphiDex® is Not Approved On or Prior to December 31, 2002
	Common Stock Closing Price Threshold	Common Stock Closing Price Threshold
<hr/>	<hr/>	<hr/>

C1A and C1B	\$6.06	\$4.28
-------------	--------	--------

Table of Contents

Option Class	MorphiDex® is Approved On or Prior to December 31, 2002	MorphiDex® is Not Approved On or Prior to December 31, 2002
	Common Stock Closing Price Threshold	Common Stock Closing Price Threshold
C2	\$9.38	\$6.62
C3	\$14.99	\$10.58
C4	\$24.50	\$17.29

If each of these share price targets are achieved resulting in the vesting of each tranche of options, the Company will record up to four non-cash compensation charges related to the vesting of certain of the options. Under performance-based options, the measurement of expense is calculated and recorded as a non-cash charge at the time performance is achieved as the difference between the market price of the stock and the exercise price of the options. If these charges are recorded by the Company in connection with the above options, they will be significant. They will, however, not result in the issuance of additional shares of Company Common Stock. The aforementioned conditions have been achieved for the Class C1A, Class C1B and Class C2 stock options, and therefore these stock options have vested. Accordingly, a non-cash compensation charge of \$15.3 million was recorded in the fourth quarter of 2000 for the vesting of the Class C1A and Class C1B stock options and a non-cash compensation charge of \$37.3 million was recorded in the third quarter of 2001 for the vesting of the Class C2 stock options. See Note 8.

The Class C1A, C1B, C2, C3 and C4 stock options are generally exercisable, if vested, upon the earlier of (i) the occurrence of a sale, disposition or transfer (Transfer) of Common Stock, after which neither Kelso & Company nor Endo Pharma LLC any longer own any shares of Common Stock or (ii) January 1, 2006.

Endo Pharma LLC 2000 Supplemental Executive and Employee Stock Option Plans

Pursuant to the Algos merger and recapitalization of the Company on July 17, 2000, the Endo Pharma LLC 2000 Supplemental Employee Stock Option Plan and the Endo Pharma LLC 2000 Supplemental Executive Stock Option Plan (collectively, the Endo Pharma LLC 2000 Supplemental Stock Option Plans) were established. The Endo Pharma LLC 2000 Supplemental Stock Option Plans reserve an aggregate of 10,672,314 shares of Common Stock of the Company held by Endo Pharma LLC for issuance. The Endo Pharma LLC 2000 Supplemental Stock Option Plans are only effective on January 1, 2003 in the event that we have not received the approval from the U.S. Food and Drug Administration (the FDA) for MorphiDex® for the treatment of pain by December 31, 2002. Stock options granted under the Endo Pharma LLC 2000 Supplemental Stock Option Plans expire no later than December 31, 2012 unless an initial public offering of the Company Common Stock held by Endo Pharma LLC occurs, in which case the stock options granted will expire on August 26, 2007. The exercise of stock options pursuant to the Endo Pharma LLC 2000 Supplemental Stock Option Plans does not result in the issuance of additional shares in the Company, however, the issuance of these stock options and/or attainment of defined common stock price targets may result in additional non-cash compensation charges to the Company. These charges may be substantial. The Endo Pharma LLC 2000 Supplemental Stock Option Plans are not currently effective, therefore no options have been granted. See Note 8.

Endo Pharmaceuticals Holdings Inc. 2000 Stock Incentive Plan

All the options we have granted pursuant to the Endo Pharmaceuticals Holdings Inc. 2000 Stock Incentive Plan have exercise prices equal to the market price of our stock on the date granted and, under accounting principles generally accepted in the United States, a measurement date had occurred on the date of grant. Consequently, we do not expect to incur a charge upon the vesting or exercise of those options.

5. WARRANTS**Class A Transferable Warrants and Class B Non-Transferable Warrants**

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 10-Q

The Class A Transferable Warrants and Class B Non-Transferable Warrants are exercisable at an exercise price of \$.01 per share into a specified number of shares of Common Stock depending on the timing of the FDA's approval of MorphiDex® for any pain indication. These warrants become exercisable on the fifth business day following the date on which we receive approval from the FDA with respect to MorphiDex® for the treatment of any pain indication. These warrants will remain exercisable for a period of six months after the exercisability date, at which time they will expire. If the FDA does not approve MorphiDex® by March 31, 2003, each of these warrants expires without any payment therefor.

Table of Contents

If the FDA approves Morphidex® on or prior to September 30, 2002, then upon exercise of these warrants, each warrant will be exercisable into 0.633803 shares of Common Stock. If the FDA approves Morphidex® after September 30, 2002 and prior to March 31, 2003, then upon exercise of these warrants, each warrant will be exercisable into 0.263158 shares of Common Stock. If the FDA does not approve Morphidex® before March 31, 2003, each of these warrants becomes void and all rights in respect of these warrants will cease. See note 8 to the Consolidated Financial Statements.

On December 5, 2001, we commenced a tender offer to purchase up to 13,500,000 of our outstanding Class A Transferable Warrants and any and all of our outstanding Class B Non-Transferable Warrants. This tender offer expired at midnight on January 25, 2002. As of December 31, 2001, there were outstanding 17,810,526 of these warrants. We accepted an aggregate of 8,585,262 Class A Transferable Warrants and Class B Non-Transferable Warrants for payment at a purchase price of \$0.75 per warrant. We used cash on hand to finance the purchase of the tendered warrants. Following the purchase by us, there are outstanding 9,225,264 of these warrants. See note 8 to the Consolidated Financial Statements.

Pre-Merger Endo Warrants

The Pre-Merger Endo Warrants are exercisable at an exercise price of \$.01 per share into a specified number of shares of Common Stock if the FDA does not approve Morphidex® for any pain indication prior to December 31, 2002. As of June 30, 2002, there were outstanding 71,328,424 of these warrants. If the FDA does not approve Morphidex® before December 31, 2002, then these warrants become exercisable and upon exercise, each warrant will be exercisable into 0.416667 shares of Common Stock for a total of 29,720,177 shares of Common Stock. See note 8 to the Consolidated Financial Statements.

6. RELATED PARTY TRANSACTIONS

On July 14, 2000, Endo Pharma LLC was formed to ensure that the stock options granted pursuant to the 1997 Employee Stock Option Plan and the 1997 Executive Stock Option Plan (collectively, as amended and restated, the Endo Pharma LLC 1997 Stock Option Plans) diluted only the pre-Merger holders of Endo Common Stock (see Note 4). Subsequent to the Merger, only currently outstanding shares of Common Stock of the Company held by Endo Pharma LLC will be issued upon the exercise of these stock options. Because Endo Pharma LLC, and not the Company, will provide the shares issued upon the exercise of the options, the Company has entered into a tax sharing agreement with Endo Pharma LLC under which the Company will pay to Endo Pharma LLC the amount of the tax benefits it receives as a result of the exercise of these stock options into shares of Common Stock held by Endo Pharma LLC for the years in which these tax benefits arise. As of June 30, 2002, approximately 1.1 million of these stock options have been exercised into shares of Common Stock held by Endo Pharma LLC by former employees. These stock option exercises may permit the Company to deduct for income tax purposes compensation of approximately \$8 million, which may result in a tax benefit amount of approximately \$3 million. Under the terms of the tax sharing agreement discussed above, the Company must pay any such tax benefit amounts to Endo Pharma LLC only upon the occurrence of a liquidity event, which is generally defined as (a) a sale of greater than 20% on a fully diluted basis of the common equity of the Company (either through a primary offering by the Company or a secondary sale by Endo Pharma LLC or a combination of both), (b) a change in control of the Company or (c) a sale of all or substantially all of the assets of the Company. In accordance with the tax sharing agreement, no payments have been made or accrued.

7. COMMITMENTS AND CONTINGENCIES

We have entered into employment agreements with certain members of management.

We have entered into certain collaboration agreements with third parties for the development of pain management products. These agreements require us to share in the development costs of such products and grant marketing rights to us for such products. If any of our third party partners are unable to fund their portion of the particular collaboration project with us, this may adversely affect our results of operations and cash flows in the foreseeable future.

Table of Contents

We are, and may in the future be, subject to various claims or legal proceedings arising out of the normal course of business with respect to commercial matters, including product liabilities, patent infringement matters, governmental regulation and other actions. We cannot predict the timing or outcome of these claims or proceedings. Currently, the Company is not involved in any claim and/or legal proceeding with respect to which the amount of ultimate liability will, in the opinion of management, materially affect our financial position, results of operations or liquidity.

8. OTHER EVENTS

On June 24, 2002, we announced the results from the first of our three Phase III clinical trials for our development product, MorphiDex®. No statistically significant difference in average daily morphine dose was observed in the morphine sulfate:dextromethorphan group compared to the morphine sulfate group. In addition, we observed no statistically significant difference in the percentage change from baseline in daily morphine dose averaged by week from the commencement of the double-blind study period to the completion of the double-blind study period. Although we expect to be able to announce the results of the second and third of these clinical trials in the fourth quarter of this year, until we are able to analyze the data from the second and third of these clinical trials, we will not be in a position to resubmit an amendment to the existing MorphiDex® new drug application with the FDA.

As described under note 5 to the consolidated financial statements in this Report, if the FDA does not approve MorphiDex® for any pain indication prior to December 31, 2002, warrants exercisable into 29,720,177 shares of Common Stock become exercisable.

In addition, as described under note 4 to the consolidated financial statements in this Report, if the FDA does not approve MorphiDex® for any pain indication prior to December 31, 2002, the Endo Pharma LLC 2000 Supplemental Stock Option Plans become effective on January 1, 2003. The Endo Pharma LLC 2000 Supplemental Stock Option Plans reserve an aggregate of 10,672,314 shares of Common Stock of the Company held by Endo Pharma LLC for issuance. Under performance-based options, the measurement of expense is calculated and recorded as a non-cash charge at the time performance is achieved as the difference between the market price of the stock and the exercise price of the options. If these charges are recorded by the Company in connection with the above options, they will be significant. They will, however, not result in the issuance of additional shares of Company Common Stock. If the Endo Pharma LLC 2000 Supplemental Stock Option Plans becomes effective, approximately 9.2 million of the 10.7 million available stock options would vest immediately. These stock options would have an exercise price of \$2.42 per share.

Finally, as described under note 4 to the consolidated financial statements in this Report, if the FDA does not approve MorphiDex® for any pain indication prior to December 31, 2002, the Common Stock Closing Price Threshold for the Endo Pharma LLC 1997 Stock Option Plans is adjusted which will result in the vesting of the outstanding Class C3 stock options and a non-cash compensation charge will be recorded for the vesting of the Class C3 stock options. Under performance-based options, the measurement of expense is calculated and recorded as a non-cash charge at the time performance is achieved as the difference between the market price of the stock and the exercise price of the options. If these charges are recorded by the Company in connection with the above options, they will be significant. They will, however, not result in the issuance of additional shares of Company Common Stock. As of June 30, 2002, approximately 6.9 million Class C3 stock options were outstanding with a weighted average exercise price of \$2.69 per share.

9. SUBSEQUENT EVENTS

On July 29, 2002, we announced that our wholly owned subsidiary, Endo Pharmaceuticals Inc., acquired BML Pharmaceuticals, Inc., a privately held company, for an up-front payment of \$14 million. In addition, upon FDA approval of BML's lead pipeline product, Immund^M, Endo Pharmaceuticals Inc. will pay the former shareholders of BML a \$32 million payment and an earn-out based on a percentage of net sales of certain products in BML's pipeline. BML will operate as a wholly owned subsidiary of Endo Pharmaceuticals Inc. We will account for the acquisition using the purchase method of accounting. In accordance with the purchase method of accounting, the purchase price will be allocated to BML's assets and liabilities based on their respective fair values on the date of the acquisition. The excess of the purchase price over the fair value of the net tangible assets will be allocated to intangible assets, including in-process research and development.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Except for the historical information contained in this Report, this Report, including the following discussion, contains forward-looking statements that involve risks and uncertainties.

Overview

We, through our wholly owned subsidiary, Endo Pharmaceuticals Inc., are engaged in the research, development, sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain. Branded products comprised approximately 76%, 67% and 63% of net sales for the years ended December 31, 2000, 2001 and the six months ended June 30, 2002, respectively. On August 26, 1997, an affiliate of Kelso & Company and the then members of management entered into an asset purchase agreement with the then DuPont Merck Pharmaceutical Company to acquire certain branded and generic pharmaceutical products and exclusive worldwide rights to a number of new chemical entities in the DuPont research and development pipeline from DuPont Merck through the newly-formed Endo Pharmaceuticals Inc.

On July 17, 2000, we completed our merger with Algos. In the merger, we issued to the former Algos stockholders, in the aggregate, 17,810,526 shares of our common stock and 17,810,526 warrants to purchase in the aggregate up to 20,575,507 additional shares of our common stock in certain circumstances as more fully described under note 5 to the consolidated financial statements in this Report. In the merger, we also issued to our pre-merger stockholders, in the aggregate, 71,328,424 warrants to purchase in the aggregate up to 29,720,177 additional shares of common stock in certain other circumstances as more fully described under note 5 to the consolidated financial statements in this Report.

The stock of Endo Pharmaceuticals Inc. is our only asset, and we have no other operations or business.

In May 2001, we entered into a long-term manufacturing and development agreement with Novartis Consumer Health, Inc., whereby Novartis has agreed to manufacture certain of our commercial products and products in development. We have incurred and expect to continue to incur significant costs associated with the preparation of Novartis' manufacturing operations under this agreement. These costs primarily relate to the preparation of test batches of drug product for FDA approval and our own quality assessment and administrative costs relating to the shifting of existing production to Novartis.

Our quarterly results have fluctuated in the past, and may continue to fluctuate. These fluctuations are primarily due to the timing of new product launches, purchasing patterns of our customers, market acceptance of our products and the impact of competitive products and pricing.

Critical Accounting Policies

To understand our financial statements, it is important to understand our accounting policies. The preparation of our financial statements in conformity with accounting principles generally accepted in the United States (generally accepted accounting principles) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. For any given individual estimate or assumption made by us, there may also be other estimates or assumptions that are reasonable. We believe, however, that given current facts and circumstances, it is unlikely that applying any such other reasonable judgment would cause a material adverse effect on our consolidated results of operations, financial position or cash flows for the periods represented in this Report.

Our most critical accounting policies include the determination of sales deductions for estimated chargebacks, rebates, sales incentives and allowances, royalties and returns and losses, the utilization of deferred tax assets and the assessment of impairment of goodwill and other intangible assets. Note 2 to our consolidated financial statements contained in our Annual Report on Form 10-K describes our significant accounting policies.



Effective January 1, 2002, we reclassified the carrying amount of workforce-in-place as goodwill. The cost of license fees is capitalized and is being amortized on a straight-line basis over their estimated useful life of twenty years. The cost of acquired patents is capitalized and is being amortized on a straight-line basis over their estimated useful life of seventeen years.

Table of Contents

The pro forma effect of the adoption of SFAS No. 141 and SFAS No. 142 is as follows:

	(Unaudited) Three Months Ended June 30,		(Unaudited) Six Months Ended June 30,	
	2002	2001	2002	2001
	(in thousands, except per share data)			
Reported net income (loss)	\$22,001	\$2,731	\$27,377	\$(11,507)

Add back: Goodwill amortization
 10,225 20,450
 Add back: Amortization of workforce-in-place
 1,487 2,974
 Less: Pro forma income tax
 (4,889) (3,935)

Adjusted net income
 \$22,001 \$9,554 \$27,377 \$7,982

Basic earnings (loss) per share:

Reported net income (loss)
 \$.22 \$.03 \$.27 \$ (.13)
 Add back: Goodwill amortization
 .11 .23
 Add back: Amortization of workforce-in-place
 .02 .03
 Less: Pro forma income tax
 (.05) (.04)

Adjusted net income
 \$.22 \$.11 \$.27 \$.09

Diluted earnings (loss) per share:

Reported net income (loss)
 \$.22 \$.03 \$.27 \$ (.13)
 Add back: Goodwill amortization
 .11 .23
 Add back: Amortization of workforce-in-place
 .02 .03
 Less: Pro forma income tax
 (.05) (.04)

Adjusted net income
 \$.22 \$.11 \$.27 \$.09

Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2001 is as follows (in thousands):

2002	\$ 741
2003	741
2004	

741
2005
741
2006
741

Compensation Related to Stock Options

During our fourth quarter ended December 31, 2000, we incurred a non-cash charge of \$15.3 million, and during our third quarter ended September 30, 2001, we recorded a non-cash charge of \$37.3 million, in each case for stock-based compensation relating to the vesting of options that were issued under the Endo Pharma LLC stock option plans. Under these plans, tranches of options vest when we attain certain stock price targets. As each tranche vests, we incur a non-cash charge representing the difference between the market price of the shares underlying the options and the exercise price of such options. We may in the future incur up to two additional charges in relation to the Endo Pharma LLC options as a result of the attainment of these common stock price targets. See "Other Events." These charges may be substantial. These options are exercisable into shares of common stock that are presently held by Endo Pharma LLC. As a result, the exercise of these options will not result in the issuance of additional shares of common stock.

In connection with the Algos merger and our related recapitalization on July 17, 2000, the Endo Pharma LLC 2000 Supplemental Employee Stock Option Plan and the Endo Pharma LLC 2000 Supplemental Executive Stock Option Plan (collectively, the "Endo Pharma LLC 2000 Supplemental Stock Option Plans") were established. The Endo Pharma LLC 2000 Supplemental Stock Option Plans reserve an aggregate of 10,672,314 shares of our

Table of Contents

common stock that is held by Endo Pharma LLC for issuance. The Endo Pharma LLC 2000 Supplemental Stock Option Plans are only effective on January 1, 2003 in the event that we have not received the approval from the FDA of MorphiDex® for the treatment of pain by December 31, 2002. The exercise of stock options pursuant to the Endo Pharma LLC 2000 Supplemental Stock Option Plans does not result in the issuance of additional shares in the Company, however, the issuance of these stock options and/or attainment of defined common stock price targets may result in additional non-cash compensation charges to the Company. These charges may be substantial. The Endo Pharma LLC 2000 Supplemental Stock Option Plans are not currently effective, therefore no options have been granted.

All the options we have granted pursuant to the Endo Pharmaceuticals Holdings Inc. 2000 Stock Incentive Plan have exercise prices equal to the market price of our stock on the date granted and, under accounting principles generally accepted in the United States, a measurement date had occurred on the date of grant. Consequently, we do not expect to incur a charge upon the vesting or exercise of those options.

Other Events

On June 24, 2002, we announced the results from the first of our three Phase III clinical trials for our development product, MorphiDex®. No statistically significant difference in average daily morphine dose was observed in the morphine sulfate:dextromethorphan group compared to the morphine sulfate group. In addition, we observed no statistically significant difference in the percentage change from baseline in daily morphine dose averaged by week from the commencement of the double-blind study period to the completion of the double-blind study period. Although we expect to be able to announce the results of the second and third of these clinical trials in the fourth quarter of this year, until we are able to analyze the data from the second and third of these clinical trials, we will not be in a position to resubmit an amendment to the existing MorphiDex® new drug application with the FDA.

As described under note 5 to the consolidated financial statements in this Report, if the FDA does not approve MorphiDex® for any pain indication prior to December 31, 2002, warrants exercisable into 29,720,177 shares of Common Stock become exercisable.

In addition, as described under note 4 to the consolidated financial statements in this Report, if the FDA does not approve MorphiDex® for any pain indication prior to December 31, 2002, the Endo Pharma LLC 2000 Supplemental Stock Option Plans become effective on January 1, 2003. The Endo Pharma LLC 2000 Supplemental Stock Option Plans reserve an aggregate of 10,672,314 shares of Common Stock of the Company held by Endo Pharma LLC for issuance. Under performance-based options, the measurement of expense is calculated and recorded as a non-cash charge at the time performance is achieved as the difference between the market price of the stock and the exercise price of the options. If these charges are recorded by the Company in connection with the above options, they will be significant. They will, however, not result in the issuance of additional shares of Company Common Stock. If the Endo Pharma LLC 2000 Supplemental Stock Option Plans becomes effective, approximately 9.2 million of the 10.7 million available stock options would vest immediately. These stock options would have an exercise price of \$2.42 per share.

Finally, as described under note 4 to the consolidated financial statements in this Report, if the FDA does not approve MorphiDex® for any pain indication prior to December 31, 2002, the Common Stock Closing Price Threshold for the Endo Pharma LLC 1997 Stock Option Plans is adjusted which will result in the vesting of the outstanding Class C3 stock options and a non-cash compensation charge will be recorded for the vesting of the Class C3 stock options. Under performance-based options, the measurement of expense is calculated and recorded as a non-cash charge at the time performance is achieved as the difference between the market price of the stock and the exercise price of the options. If these charges are recorded by the Company in connection with the above options, they will be significant. They will, however, not result in the issuance of additional shares of Company Common Stock. As of June 30, 2002, approximately 6.9 million Class C3 stock options were outstanding with a weighted average exercise price of \$2.69 per share.

Table of Contents

Net Sales

Our net sales consist of revenues from sales of our pharmaceutical products, less estimates for certain chargebacks, rebates, sales incentives and allowances, royalties and the cost of returns and losses. We estimate the accrual for sales deductions based on historical data, estimated future trends and other competitive factors. Net sales are recognized when products are shipped.

The following table presents our unaudited net sales by product category for the three months and six months ended June 30, 2002 and 2001.

	Three Months Ended June 30,		Six Months Ended June 30,	
	2002	2001	2002	2001
	(in thousands, unaudited)			
Percocet®	\$40,610	\$36,242	\$64,078	\$56,401
Lidoderm®	25,834	7,022	35,836	10,665
Other brands	4,295	3,589	9,621	8,591

Total brands	\$70,739	\$46,853	\$109,535	\$75,657
Total generics	\$37,163	\$21,004	\$65,393	\$31,582

Total net sales	\$107,902	\$67,857	\$174,928	\$107,239
-----------------	-----------	----------	-----------	-----------

The following table presents our unaudited net sales of select products as a percentage of total net sales for the three months and six months ended June 30, 2002 and 2001.

	Three Months Ended June 30,		Six Months Ended June 30,	
	2002	2001	2002	2001
Percocet®	38%	54%	37%	53%
Lidoderm®				
24 10 20 10				
Other brands				
4 5 6 8				
(unaudited)				
Total brands				
66 69 63 71				
Total generics				
34 31 37 29				
Total net sales	100%	100%	100%	100%

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 10-Q

Three Months Ended June 30, 2002 Compared to the Three Months Ended June 30, 2001

Net sales for the three months ended June 30, 2002 increased by 59% to \$107.9 million from \$67.9 million in the comparable 2001 period. This increase in net sales was primarily due to the increase in net sales of Lidoderm®, the first FDA-approved product for the treatment of the pain of post-herpetic neuralgia, certain generic products and the new strengths of Percocet®. In September 1999, we launched Lidoderm®, which continues to gain market share due to our ongoing promotional and educational efforts. Net sales of Lidoderm® increased to \$25.8 million from \$7.0 million in the comparable 2001 period. Percocet® net sales increased 12% to \$40.6 million from \$36.2 million in the comparable 2001 period due to the new strengths of Percocet® launched in November 2001. In April 2001, generic equivalents of Percocet® 7.5/500 and Percocet® 10.0/650 were introduced. In November 2001, we launched Percocet® 7.5/325 and Percocet® 10.0/325 which do not currently have generic equivalents. Generic products increased 77% to \$37.2 million from \$21.0 million in the comparable 2001 period primarily due to the growth of our generic morphine sulfate extended release tablets and Endocet®. In November 1998, we launched the 15mg, 30mg

Table of Contents

and 60mg strengths, in May 2001, we launched the 100mg strength and in September 2001, we launched the 200mg strength of our generic morphine sulfate extended release tablets. These products continue to gain market share. In April 2001, we launched two new strengths of our generic product Endocet®. Generic competition with our products may have a material impact on our results of operations and cash flows in the future.

Gross profit for the three months ended June 30, 2002 increased by 71% to \$80.1 million from \$46.8 million in the comparable 2001 period. Gross profit margins increased to 74% from 69% due to a more favorable mix of higher margin brand and generic products resulting from the product launches discussed above, and the discontinuation of some lower margin non-core products. In addition, the increase in gross profit margins was also due to the existing fixed cost nature of our manufacturing relationship with Bristol-Myers Squibb Pharma Company (formerly DuPont Pharmaceuticals), currently our most significant contract manufacturing relationship. If we achieve our forecast for revenue and product mix, we expect the increase in gross profits and gross profit margins to continue.

Selling, general and administrative expenses for the three months ended June 30, 2002 increased by 42% to \$27.6 million from \$19.5 million in the comparable 2001 period. This increase was due to a \$3.5 million increase in sales and promotional efforts in 2002 over the comparable 2001 period to support Lidoderm® and Percocet®. In addition, we experienced an increase in personnel-related costs in the general and administrative functions in order to support our new product marketing and new product development.

Research and development expenses for the three months ended June 30, 2002 increased by 82% to \$15.1 million from \$8.3 million in the comparable 2001 period. This increase was due to our increased spending on new products under development that are focused in pain management. We are currently conducting Phase III clinical trials on MorphiDex® and on both an oral extended-release and oral immediate-release version of oxymorphone.

Depreciation and amortization for the three months ended June 30, 2002 decreased to \$.7 million from \$12.4 million in the comparable 2001 period. Effective January 1, 2002, we have adopted the provisions of SFAS No. 142, Goodwill and Other Intangible Assets, and will no longer amortize goodwill unless evidence of an impairment exists. If SFAS No. 142 had been adopted as of January 1, 2001, depreciation and amortization for the three months ended June 30, 2001 would have been \$.7 million.

Interest expense, net for the three months ended June 30, 2002 decreased by 45% to \$1.6 million from \$2.9 million in the comparable 2001 period. This decrease is substantially due to the repayment on October 29, 2001 of the term loans outstanding under our credit facility. Interest expense for the three months ended June 30, 2002 substantially represents the accretion of promissory notes issued to Bristol-Myers Squibb which bear no interest and therefore have been discounted in the accompanying financial statements.

Income tax for the three months ended June 30, 2002 increased to \$13.1 million from \$1.0 million in the comparable 2001 period. This increase is due to the increase in income before income tax for the three months ended June 30, 2002. For the three months ended June 30, 2001, we recorded a valuation allowance on our existing deferred tax assets due to the uncertainty of the utilization of such amounts in the foreseeable future. During the fourth quarter of 2001, we evaluated our anticipated future taxable income based upon the repayment of our outstanding term loans, new product approvals and other existing and estimated future product performance and determined that it is more likely than not that we will utilize our deferred tax benefits. Accordingly, we reversed our valuation reserves that had been recorded against those deferred tax assets.

Six Months Ended June 30, 2002 Compared to the Six Months Ended June 30, 2001

Net sales for the six months ended June 30, 2002 increased by 63% to \$174.9 million from \$107.2 million in the comparable 2001 period. This increase in net sales was primarily due to the increase in net sales of Lidoderm®, the first FDA-approved product for the treatment of the pain of post-herpetic neuralgia, certain generic products and the new strengths of Percocet®. In September 1999, we launched Lidoderm®, which continues to gain market share due to our ongoing promotional and educational efforts. Net sales of Lidoderm® increased to \$35.8 million from \$10.7 million in the comparable 2001 period. Percocet® net sales increased 14% to \$64.1 million from \$56.4 million in the comparable 2001 period due to the new strengths of Percocet® launched in November 2001. In April 2001, generic equivalents of Percocet® 7.5/500 and Percocet® 10.0/650 were introduced. In November 2001, we launched

Table of Contents

Percocet® 7.5/325 and Percocet® 10.0/325 which do not currently have generic equivalents. Generic products increased 107% to \$65.4 million from \$31.6 million in the comparable 2001 period primarily due to the growth of our generic morphine sulfate extended release tablets and Endocet®. In November 1998, we launched the 15mg, 30mg and 60mg strengths, in May 2001, we launched the 100mg strength and in September 2001, we launched the 200mg strength of our generic morphine sulfate extended release tablets. These products continue to gain market share. In April 2001, we launched two new strengths of our generic product Endocet®. Generic competition with our products may have a material impact on our results of operations and cash flows in the future.

Gross profit for the six months ended June 30, 2002 increased by 74% to \$128.2 million from \$73.6 million in the comparable 2001 period. Gross profit margins increased to 73% from 69% due to a more favorable mix of higher margin brand and generic products resulting from the product launches discussed above, and the discontinuation of some lower margin non-core products. In addition, the increase in gross profit margins was also due to the existing fixed cost nature of our manufacturing relationship with Bristol-Myers Squibb Pharma Company (formerly DuPont Pharmaceuticals), currently our most significant contract manufacturing relationship. If we achieve our forecast for revenue and product mix, we expect the increase in gross profits and gross profit margins to continue.

Selling, general and administrative expenses for the six months ended June 30, 2002 increased by 45% to \$51.1 million from \$35.3 million in the comparable 2001 period. This increase was due to a \$7.7 million increase in sales and promotional efforts in 2002 over the comparable 2001 period to support Lidoderm® and Percocet®. In addition, we experienced an increase in personnel-related costs in the general and administrative functions in order to support our new product marketing and new product development.

Research and development expenses for the six months ended June 30, 2002 increased by 63% to \$28.5 million from \$17.5 million in the comparable 2001 period. This increase was due to our increased spending on new products under development that are focused in pain management. We are currently conducting Phase III clinical trials on MorphoDex® and on both an oral extended-release and oral immediate-release version of oxymorphone.

Depreciation and amortization for the six months ended June 30, 2002 decreased to \$1.5 million from \$24.8 million in the comparable 2001 period. Effective January 1, 2002, we have adopted the provisions of SFAS No. 142, Goodwill and Other Intangible Assets, and will no longer amortize goodwill unless evidence of an impairment exists. If SFAS No. 142 had been adopted as of January 1, 2001, depreciation and amortization for the six months ended June 30, 2001 would have been \$1.4 million.

Interest expense, net for the six months ended June 30, 2002 decreased by 48% to \$3.3 million from \$6.4 million in the comparable 2001 period. This decrease is substantially due to the repayment on October 29, 2001 of the term loans outstanding under our credit facility. Interest expense for the six months ended June 30, 2002 substantially represents the accretion of promissory notes issued to Bristol-Myers Squibb which bear no interest and therefore have been discounted in the accompanying financial statements. For the six months ended June 30, 2001, due to the adoption of SFAS No. 133 on January 1, 2001, the Company recorded a \$.2 million charge for the accumulated transition adjustment relating to derivative instruments that do not qualify as a hedge under SFAS No. 133.

Income tax for the six months ended June 30, 2002 increased to \$16.4 million from \$1.0 million in the comparable 2001 period. This increase is due to the increase in income before income tax for the six months ended June 30, 2002. For the six months ended June 30, 2001, we recorded a valuation allowance on our existing deferred tax assets due to the uncertainty of the utilization of such amounts in the foreseeable future. During the fourth quarter of 2001, we evaluated our anticipated future taxable income based upon the repayment of our outstanding term loans, new product approvals and other existing and estimated future product performance and determined that it is more likely than not that we will utilize our deferred tax benefits. Accordingly, we reversed our valuation reserves that had been recorded against those deferred tax assets.

Table of Contents

Liquidity and Capital Resources

Net cash provided by operating activities increased by \$24.7 million to \$64.0 million for the six months ended June 30, 2002 from \$39.3 million for the six months ended June 30, 2001. This increase was due to the cash provided by the increase in net sales and gross profit for the six months ended June 30, 2002 compared to the six months ended June 30, 2001 offset by an increase in selling, general and administrative expenses and research and development expenses for the six months ended June 30, 2002 as compared to the six months ended June 30, 2001.

Net cash utilized in investing activities decreased by \$1.2 million to \$.8 million for the six months ended June 30, 2002 from \$2.0 million for the six months ended June 30, 2001 due to the purchase in 2001 of leasehold improvements and other furniture and fixtures related to our principal executive offices and the implementation of an electronic document management system during 2001.

Net cash utilized in financing activities decreased by \$22.8 million to \$6.7 million for the six months ended June 30, 2002 from \$29.5 million for the six months ended June 30, 2001. During the six months ended June 30, 2002, we utilized \$6.7 million of cash, including fees, to repurchase 8.6 million Class A Transferable Warrants and Class B Non-Transferable Warrants. During the six months ended June 30, 2001, we made the scheduled principal payments on our term loans which were repaid in full on October 29, 2001.

In its annual report filed on Form 10-K for the year ended December 31, 2001, Penwest Pharmaceuticals Co., a collaboration partner of Endo with which Endo has an alliance agreement and with which Endo is developing one of its pipeline projects, stated that its existing capital resources, will enable Penwest to maintain currently planned operations at least through March 31, 2003. If Penwest is unable to fund their portion of the collaboration project with Endo, this may adversely affect our results of operations and cash flows in the foreseeable future.

Our cash and cash equivalents totaled \$151.8 million at June 30, 2002. We believe that our (a) cash and cash equivalents, (b) cash flow from operations and (c) our credit facility (which has an available unused line of credit of \$75 million) will be sufficient to meet our normal operating, investing and financing requirements in the foreseeable future, including the funding of our pipeline projects in the event that our collaboration partners are unable to fund their portion of any particular project. We may use a portion of our cash and cash equivalents to repay all or a portion of the notes that we have issued to Bristol-Myers Squibb Company (formerly DuPont Pharmaceuticals) or for possible acquisitions.

In December 2001, we amended and restated our senior secured credit facility with a number of lenders, including affiliates of certain of the underwriters of our recent public offering. This amended and restated credit facility provides for a line of credit of \$75.0 million and a delayed draw term loan of \$25.0 million. The line of credit and delayed draw term loan mature December 21, 2006. Any loans outstanding under the credit facility are secured by a first priority security interest in substantially all of our assets. The credit facility contains representations and warranties, covenants, events of default and other provisions customarily found in similar agreements.

On July 29, 2002, we announced that our wholly owned subsidiary, Endo Pharmaceuticals Inc., acquired BML Pharmaceuticals, Inc., a privately held company, for an up-front payment of \$14 million. In addition, upon FDA approval of BML's lead pipeline product, ImmunolTM, Endo Pharmaceuticals Inc. will pay the former shareholders of BML a \$32 million payment and an earn-out based on a percentage of net sales of certain products in BML's pipeline.

Item 3. *Quantitative and Qualitative Disclosures about Market Risk.*

During the fourth quarter of 2001, we repaid the remaining outstanding balance of our variable rate term loans. Prior to the repayment of our variable rate term loans, our primary market risk exposure was to changes in interest rates (LIBOR) on our variable rate borrowings. As of June 30, 2002, we only have outstanding fixed rate borrowings. These fixed rate borrowings are substantially comprised of promissory notes payable to Bristol-Myers Squibb issued in consideration for manufacturing and supply services provided under the Manufacturing and Supply Agreement. The promissory notes issued annually over the initial five-year term of the Manufacturing and Supply Agreement have an aggregate face value of \$23.0 million per year and are payable on August 26, 2002. The

Table of Contents

promissory notes bear no interest and therefore have been discounted in the accompanying financial statements using our borrowing rate for similar instruments at the time of borrowing. We also financed a portion of the purchase price of the August 26, 1997 acquisition from DuPont through the issuance of a promissory note to DuPont. The note has a face value of \$3.9 million and is payable on August 26, 2002. The promissory note bears no interest and therefore has been discounted in the accompanying financial statements using a rate which approximates our borrowing rate for similar instruments at the time of borrowing. On December 21, 2001, we entered into a new credit facility that provides for a line of credit of \$75.0 million and a delayed draw term loan of \$25.0 million. Borrowings under the new credit facility are variable rate borrowings. There are no amounts outstanding under the new credit facility. We do not utilize financial instruments for trading purposes and hold no derivative financial instruments that could expose us to significant market risk. We monitor interest rates and enter into interest rate agreements as considered appropriate.

Table of Contents

PART II

OTHER INFORMATION

Item 1. Legal Proceedings.

Purdue Pharma L.P., et al. v. Endo Pharmaceuticals Inc., et al., Index No. 00 Civ. 8029 (SHS) (S.D.N.Y.); Purdue Pharma L.P., et al. v. Endo Pharmaceuticals Inc., et al., Index No. 01 Civ. 2109 (SHS) (S.D.N.Y.); Purdue Pharma L.P., et al. v. Endo Pharmaceuticals Inc., et al., Index No. 01 Civ. 8177 (SHS) (S.D.N.Y.)

On October 20, 2000, The Purdue Frederick Company and related companies (Purdue Frederick) filed suit against us and our subsidiary, Endo Pharmaceuticals Inc. (EPI), in the U.S. District Court for the Southern District of New York alleging that EPI's bioequivalent version of Purdue Frederick's OxyContin® (oxycodone hydrochloride extended-release tablets), 40mg strength, infringes three of its patents. This suit arose after EPI provided the plaintiffs with notice that its ANDA submission for a bioequivalent version of Purdue Frederick's OxyContin®, 40mg strength, challenged the listed patents for OxyContin® 40mg tablets. On March 13, 2001, Purdue Frederick filed a second suit against us and EPI in the U.S. District Court for the Southern District of New York alleging that EPI's bioequivalent versions of Purdue Frederick's OxyContin®, 10mg and 20mg strengths, infringe the same three patents. This suit arose from EPI having amended its earlier ANDA on February 9, 2001 to add bioequivalent versions of the 10mg and 20mg strengths of OxyContin®. On August 30, 2001, Purdue Frederick filed a third suit against us and EPI in the U.S. District Court for the Southern District of New York alleging that EPI's bioequivalent version of Purdue Frederick's OxyContin®, 80mg strength, infringes the same three patents. This suit arose from EPI having amended its earlier ANDA on July 30, 2001 to add the bioequivalent version of the 80mg strength of OxyContin®.

For each of the 10mg, 20mg, 40mg and 80mg strengths of this product, EPI made the required Paragraph IV certification against the patents listed in the FDA's Orange Book as covering these strengths of OxyContin®. EPI has pleaded counterclaims that the patents asserted by Purdue Frederick are invalid, unenforceable and/or not infringed by EPI's formulation of oxycodone hydrochloride extended-release tablets, 10mg, 20mg, 40mg and 80mg strengths. EPI has also counterclaimed for antitrust damages based on allegations that Purdue Frederick obtained the patents through fraud on the United States Patent and Trademark Office and is asserting them while aware of their invalidity and unenforceability. However, we cannot make any assurances as to the outcome of this patent challenge. Purdue Frederick was granted a preliminary injunction (*Purdue Pharma L.P. v. Boehringer Ingelheim GmbH*, 98 F. Supp. 2d 362 (SDNY 2000)), which decision was affirmed on appeal (*Purdue Pharma L.P. v. Boehringer Ingelheim GmbH*, 237 F.3d 1359 (Fed. Cir. 2001)), against a different manufacturer based on the same patents that are being asserted against us and EPI, and in the same court in which Purdue Frederick sued. We believe the defenses rejected in the preliminary injunction decision and in the appellate decision do not substantially impact the principal defenses raised by us and EPI.

SmithKline Beecham Corporation, et al. v. Endo Pharmaceuticals Inc., Index No. 01 Civ. 5770 (E.D. Pa.)

On November 15, 2001, SmithKline Beecham Corporation (and related companies) filed suit against EPI in the U.S. District Court for the Eastern District of Pennsylvania alleging that EPI's bioequivalent version of SmithKline's Paxil®, 40 mg strength, infringes five of its patents. The FDA accepted EPI's ANDA submission for a bioequivalent version of SmithKline's Paxil®, 40 mg strength, earlier in 2001. In this ANDA, EPI made the required Paragraph IV certification against all of the SmithKline patents listed in the FDA's Orange Book as covering Paxil®. Paxil® is indicated for the treatment of depression, obsessive compulsive disorder and panic disorder. For strategic reasons, on May 9, 2002, we submitted to the FDA a request to withdraw of this ANDA. As a result, Endo has sought to have the pending action dismissed. On August 2, 2002, the parties filed with the court a Stipulation and Consent Order dismissing this action, with each party bearing its own legal costs.

Litigation similar to that described above may also result from products we currently have in development, as well as those that we may develop in the future. We, however, cannot predict the timing or outcome of any such litigation, or whether any such litigation will be brought against us.

Table of Contents

Toombs v. Bayer Corp., et al., No. 3:01CV2280 (W.D. La.); In Re: PPA Products Liability Litigation, MDL No. 1407 (W.D. Wash.)

On November 15, 2001, EPI was named, along with ten other pharmaceutical companies, as a defendant in a class action lawsuit filed by Bennie Toombs in the United States District Court for the Western District of Louisiana. According to the complaint, each of the defendant pharmaceutical companies had allegedly manufactured and sold products containing phenylpropanolamine (PPA). The complaint alleges that the defendants failed to adequately warn plaintiff of the hazards of the use of the subject products containing PPA and that as a result of this failure to warn, plaintiffs suffered injury. In December 2001, the action was transferred by order of the United States Judicial Panel on Multidistrict Litigation to the Western District of Washington. On June 5, 2002, the presiding judge granted defendants' motion to strike the class action allegations contained in the plaintiff's complaint, thereby rendering the Toombs case an individual action by the named plaintiff. In discovery obtained from the named plaintiff, it appears that the named plaintiff never actually used or consumed a PPA-containing product manufactured or sold by EPI. Accordingly, the named plaintiff agreed to dismiss its claims against EPI and, on July 25, 2002, a notice of dismissal was filed with the court.

Rowe, et al. v. Bayer Corp., et al., No. 02-1833 (E.D. La.); Landry, et al. v. Bayer Corp., et al., No. 02-1835, (E.D. La.); Everidge, et al. v. Bayer Corp., et al., No. 02-1834 (E.D. La.); Ackel, et al. v. Bayer Corp., et al., No. 02-1831 (E.D. La.); McCullough, et al. v. American Home Products Corp., et al., No. CV02-1295-S (W.D. La.); Ashton, et al. v. Bayer Corp., et al., No. 02-598 (M.D. La.)

On June 17, 2002, EPI was named, along with ten other pharmaceutical companies, as a defendant in four lawsuits filed by groups of 28, 34, 37, and 43 individual plaintiffs, respectively, in the United States District Court for the Eastern District of Louisiana. On June 18, 2002, EPI was named, along with ten other pharmaceutical companies, as a defendant in a lawsuit filed by Ellen McCullough and Brenda Businelle in the United States District Court for the Western District of Louisiana. On June 21, 2002, EPI was named, along with ten other pharmaceutical companies, as a defendant in a lawsuit filed by Joyce Ashton and Bernadine Johnson in the United States District Court for the Middle District of Louisiana. According to each of these six complaints, each of the defendant pharmaceutical companies allegedly manufactured and sold products containing phenylpropanolamine (PPA). Each complaint alleges that the defendants failed to adequately warn plaintiff of the hazards of the use of the subject products containing PPA and that as a result of this failure to warn, plaintiffs suffered injury. To date, EPI has not been served with a summons in any of the six cases. Each of these six cases except *McCullough, et al. v. American Home Products Corp., et al.*, are in the process of being transferred to the United States District Court for the Western District of Washington by order of the United States Judicial Panel on Multidistrict Litigation. Once the transfer is complete, the plaintiffs' claims in those cases will become subject to discovery. It is likely that the *McCullough* case will also be transferred to the United States District Court for the Western District of Washington at some point. EPI intends to defend itself vigorously in each of these cases.

General

In addition to the above, the Company is involved in, or has been involved in, arbitrations or legal proceedings that arise from the normal course of its business. The Company cannot predict the timing or outcome of these claims and proceedings. Currently, the Company is not involved in any arbitration and/or legal proceeding that it expects to have a material effect on its business, financial condition or results of operations and cash flows.

Item 2. Changes in Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Table of Contents

Item 4. *Submission of Matters to a Vote of Security Holders.*

- (a) The annual meeting of the stockholders of the Company was held on May 23, 2002.
- (b) The stockholders elected all of the Company's nominees for director. The stockholders also approved the appointment of Deloitte & Touche LLP as the Company's independent auditors for 2002.

(1) *Election of Directors:*

	For	Against
Carol A. Ammon	69,979,016	0
Michael B. Goldberg	69,979,016	0
Michael Hyatt	69,979,016	0
Roger H. Kimmel	69,979,016	0
Frank J. Loverro	69,979,016	0
Michael W. Mitchell	69,979,016	0
Joseph T. O'Donnell, Jr.	69,979,016	0
David I. Wahrhaftig	69,979,016	0

(2) *Approval of Appointment of Deloitte & Touche LLP*

For	69,979,016
Against	0

The foregoing matters are described in detail in the Company's information statement dated April 26, 2002, for the Annual Meeting of Stockholders held on May 23, 2002.

Item 5. *Other Information.*

None.

Table of Contents

Item 6. Exhibits and Reports on Form 8-K.

(a) *Exhibits.*

The information called for by this item is incorporated by reference to the Exhibit Index of this Report.

(b) *Reports on Form 8-K.*

We filed the following Form 8-Ks in the quarter ended June 30, 2002:

Dates	Items
April 25, 2002	Items 7 & 9
May 1, 2002	
Items 7 & 9	
June 24, 2002	
Items 5 & 7	
June 25, 2002	
Items 7 & 9	

No financial statements were filed in connection with any such Form 8-K.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ENDO PHARMACEUTICALS HOLDINGS INC.
(Registrant)

/s/ CAROL A.
AMMON

Name: Carol A.
Ammon Title:
*Chairman and
Chief Executive
Officer* /s/
JEFFREY R.
BLACK

Name: Jeffrey R.
Black Title:
*Senior Vice
President and
Chief Financial
Officer*

Date: August 14, 2002

Table of Contents**Exhibit Index**

Exhibit No.	Title
2.1	Amended and Restated Agreement and Plan of Merger, dated as of March 3, 2000 (the Merger Agreement), by and among Endo Pharmaceuticals Holdings Inc. (Endo), Endo Inc. and Algos Pharmaceutical Corporation (Algos) (incorporated herein by reference to Exhibit 2.1 of the Registration Statement on Form S-4 of the Registrant (Registration No. 333-39040) (the Registration Statement), filed with the Securities and Exchange Commission (the Commission) on June 9, 2000)
2.2	Amendment, dated as of April 17, 2000, to the Merger Agreement, by and between Endo, Endo Inc. and Algos (incorporated herein by reference to Exhibit 2.2 of the Registration Statement filed with the Commission on June 9, 2000)
2.3	Asset Purchase Agreement, dated as of August 27, 1997, by and between Endo Pharmaceuticals Inc. (Endo Pharmaceuticals) and The DuPont Merck Pharmaceutical Company (DuPont Merck Pharmaceutical) (incorporated herein by reference to Exhibit 2.3 of the Registration Statement filed with the Commission on June 9, 2000)
3.1	Amended and Restated Certificate of Incorporation of Endo (incorporated

herein by
reference to
Exhibit 3.1 of the
Form 10-Q for
the Quarter ended
June 30, 2000
filed with the
Commission on
August 15,
2000)3.2
Amended and
Restated By-laws
of Endo
(incorporated
herein by
reference to
Exhibit 3.2 of the
Form 10-Q for
the Quarter ended
June 30, 2000
filed with the
Commission on
August 15,
2000)4.1
Amended and
Restated
Executive
Stockholders
Agreement, dated
as of July 14,
2000, by and
among Endo,
Endo Pharma
LLC (Endo
LLC), Kelso
Investment
Associates V,
L.P. (KIA V),
Kelso Equity
Partners V, L.P.
(KEP V) and the
Management
Stockholders (as
defined therein)
(incorporated
herein by
reference to
Exhibit 4.1 of the
Form 10-Q for
the Quarter ended
June 30, 2000
filed with the
Commission on
August 15,
2000)4.2
Amended and
Restated
Employee
Stockholders
Agreement, dated
as of July 14,
2000, by and

among Endo,
Endo LLC, KIA
V, KEP V and
the Employee
Stockholders (as
defined therein)
(incorporated
herein by
reference to
Exhibit 4.2 of the
Form 10-Q for
the Quarter ended
June 30, 2000
filed with the
Commission on
August 15,
2000)4.3 Form
of Stock
Certificate of
Endo Common
Stock
(incorporated
herein by
reference to
Exhibit 4.3 of the
Form 10-Q for
the Quarter ended
June 30, 2000
filed with the
Commission on
August 15,
2000)4.4
Registration
Rights
Agreement, dated
as of July 17,
2000, by and
between Endo
and Endo LLC
(incorporated
herein by
reference to
Exhibit 4.4 of the
Form 10-Q for
the Quarter ended
June 30, 2000
filed with the
Commission on
August 15,
2000)10.1 Endo
Warrant
Agreement, dated
as of July 17,
2000, by and

Table of Contents

Exhibit No.	Title
	between Endo and United States Trust Company of New York (incorporated herein by reference to Exhibit 10.1 of the Form 10-Q for the Quarter ended June 30, 2000 filed with the Commission on August 15, 2000)10.2 Algos Warrant Agreement, dated as of July 17, 2000, by and between Endo and United States Trust Company of New York (incorporated herein by reference to Exhibit 10.2 of the Form 10-Q for the Quarter ended June 30, 2000 filed with the Commission on August 15, 2000)10.3 Form of Series A Warrant to Purchase Shares of Common Stock and Warrants of Endo (incorporated herein by reference to Exhibit 10.3 of the Registration Statement filed with the Commission on June 9, 2000)10.4 Letter Agreement, dated as of November 26, 1999, by and among Algos, Endo, KIA V and

KEP V
(incorporated
herein by
reference to
Exhibit 10.4 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.5 Tax
Sharing
Agreement, dated
as of July 17,
2000, by and
among Endo,
Endo Inc. and
Endo LLC
(incorporated
herein by
reference to
Exhibit 10.5 of
the Form 10-Q
for the Quarter
ended June 30,
2000 filed with
the Commission
on August 15,
2000)10.6
[Intentionally
Omitted.]10.7
Amended and
Restated Credit
Agreement, dated
as of December
21, 2001, by and
between Endo,
Endo
Pharmaceuticals,
the Lenders Party
There to and
JPMorgan Chase
Bank
(incorporated by
reference to
Exhibit 10.7 of
the Annual
Report on
Form 10-K for
the Year Ended
December 31,
2001 filed with
the Commission
on March 29,
2002)10.8
[Intentionally
Omitted.]10.9
[Intentionally
Omitted.]10.10
Sole and
Exclusive
License

Agreement, dated
as of November
23, 1998, by and
between Endo
Pharmaceuticals
and Hind Health
Care, Inc.

(incorporated
herein by
reference to
Exhibit 10.10 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.11

Analgesic
License

Agreement, dated
as of October 27,
1997, by and
among Endo
Pharmaceuticals,
Endo

Laboratories,
LLC and DuPont
Merck

Pharmaceutical
(incorporated
herein by
reference to

Exhibit 10.11 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.12

Anti-Epileptic
License

Agreement, dated
as of October 27,
1997, by and
among Endo
Pharmaceuticals,
Endo

Laboratories,
LLC and DuPont
Merck

Pharmaceutical
(incorporated
herein by
reference to

Exhibit 10.12 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.13

[Intentionally

Omitted.]10.14
Supply and
Manufacturing
Agreement, dated
as of
November 23,
1998, by and
between Endo
Pharmaceuticals
and Teikoku
Seiyaku Co., Ltd
(incorporated
herein by
reference to
Exhibit 10.14 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.15
Supply
Agreement, dated
as of July 1,
1998, by and
between Endo
Pharmaceuticals
and Mallinckrodt
Inc.
(Mallinckrodt)
(incorporated
herein by
reference to
Exhibit 10.15 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.16
Supply
Agreement for
Bulk Narcotics
Raw Materials,
dated as of
July 1, 1998, by
and between
Endo
Pharmaceuticals
and

Table of Contents

Exhibit No.	Title
	<p>Mallinckrodt (incorporated herein by reference to Exhibit 10.16 of the Registration Statement filed with the Commission on June 9, 2000)10.17 Manufacture and Supply Agreement, dated as of August 26, 1997, by and among Endo Pharmaceuticals, DuPont Merck Pharmaceutical and DuPont Merck Pharma (n/k/a Bristol-Myers Squibb Pharma Company) (incorporated herein by reference to Exhibit 10.17 of the Registration Statement filed with the Commission on June 9, 2000)10.18 Amended and Restated Strategic Alliance Agreement, dated as of April 2, 2002, by and between Endo Pharmaceuticals and Penwest Pharmaceuticals Co. (incorporated herein by reference to Exhibit 10.18 of the Quarterly Report on Form 10-Q for the Quarter Ended March 31,</p>

2002 filed with
the Commission
on May 14,
2002)10.19
Agreement, dated
as of February 1,
2000, by and
between Endo
Pharmaceuticals
and UPS Supply
Chain
Management,
Inc. (f/k/a/
Livingston
Healthcare
Services Inc.)
(incorporated
herein by
reference to
Exhibit 10.19 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.20
Medical Affairs
Support Services
Agreement, dated
as of June 1,
1999, by and
between Endo
Pharmaceuticals
and Kunitz and
Associates, Inc.
(incorporated
herein by
reference to
Exhibit 10.20 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)*10.21
Endo
Pharmaceuticals
Holdings Inc.
2000 Stock
Incentive Plan
(incorporated
herein by
reference to
Exhibit 10.21 of
the Quarterly
Report on
Form 10-Q for
the Quarter
Ended
September 30,
2000 filed with
the Commission

on November 13,
2000)*10.22
Endo LLC
Amended and
Restated 1997
Employee Stock
Option Plan
(incorporated
herein by
reference to
Exhibit 10.22 of
the Quarterly
Report on
Form 10-Q for
the Quarter
Ended
September 30,
2000 filed with
the Commission
on November 13,
2000)*10.23
Endo LLC
Amended and
Restated 1997
Executive Stock
Option Plan
(incorporated
herein by
reference to
Exhibit 10.23 of
the Quarterly
Report on
Form 10-Q for
the Quarter
Ended
September 30,
2000 filed with
the Commission
on November 13,
2000)*10.24
Endo LLC 2000
Amended and
Restated
Supplemental
Employee Stock
Option Plan
(incorporated
herein by
reference to
Exhibit 10.24 of
the Quarterly
Report on
Form 10-Q for
the Quarter
Ended
September 30,
2000 filed with
the Commission
on November 13,
2000)*10.25
Endo LLC 2000
Amended and

Restated
Supplemental
Executive Stock
Option Plan
(incorporated
herein by
reference to
Exhibit 10.25 of
the Quarterly
Report on
Form 10-Q for
the Quarter
Ended
September 30,
2000 filed with
the Commission
on November 13,
2000)*10.26
Employment
Agreement, dated
as of July 17,
2000, by and
between Endo
and John W. Lyle
(incorporated
herein by
reference to
Exhibit 10.26 of
the Form 10-Q
for the Quarter
ended June 30,
2000 filed with
the Commission
on August 14,
2000)*10.27
Amended and
Restated
Employment
Agreement, dated
as of
September 1,
2001, by and
between Endo
Pharmaceuticals
and Carol A.
Ammon
(incorporated
herein by
reference to
Exhibit 10.27 of
the Current
Report on
Form 8-K dated
August 31,

Table of Contents

Exhibit No.	Title
<p>2001)*10.28 Amended and Restated Employment Agreement, dated as of September 1, 2001, by and between Endo Pharmaceuticals and Jeffrey R. Black (incorporated herein by reference to Exhibit 10.28 of the Current Report on Form 8-K dated August 31, 2001)*10.29 Amended and Restated Employment Agreement, dated as of September 1, 2001, by and between Endo Pharmaceuticals and David Allen Harvey Lee, MD, Ph.D. (incorporated herein by reference to Exhibit 10.29 of the Current Report on Form 8-K dated August 31, 2001)*10.30 Amended and Restated Employment Agreement, dated as September 1, 2001, by and between Endo Pharmaceuticals and Mariann T. MacDonald (incorporated herein by reference to Exhibit 10.30 of</p>	

the Current
Report on
Form 8-K dated
August 31,
2001)10.31
Separation and
Release
Agreement, dated
as of March 22,
2000, by and
between Endo
Pharmaceuticals,
Endo and Osagie
O. Imasogie
(incorporated
herein by
reference to
Exhibit 10.31 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.32
Separation and
Release
Agreement, dated
as of April 20,
2000, by and
between Endo
Pharmaceuticals,
Endo and Louis
J. Vollmer
(incorporated
herein by
reference to
Exhibit 10.32 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.33
Office Lease,
dated as of
August 26, 1997,
by and between
Endo
Pharmaceuticals
and Northstar
Development
Company
(incorporated
herein by
reference to
Exhibit 10.33 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)10.34

Lease
Agreement, dated
as of May 5,
2000, by and
between Endo
Pharmaceuticals
and Painters
Crossing One
Associates, L.P.
(incorporated
herein by
reference to
Exhibit 10.34 of
the Registration
Statement filed
with the
Commission on
June 9,
2000)*10.35
Amended and
Restated
Employment
Agreement, dated
as of
September 1,
2001, by and
between Endo
and Caroline B.
Manogue
(formerly Berry)
(incorporated
herein by
reference to
Exhibit 10.35 of
the Current
Report on
Form 8-K dated
August 31,
2001)*10.36
Amended and
Restated
Employment
Agreement, dated
as of
September 1,
2001, by and
between Endo
and Peter A.
Lankau
(incorporated
herein by
reference to
Exhibit 10.36 of
the Current
Report on
Form 8-K dated
August 31,
2001)10.37
License
Agreement, dated
as of August 16,
1993, by and

between Endo
Pharmaceuticals
(as successor in
interest to Algos
Pharmaceutical
Corporation) and
The Medical
College of
Virginia
(incorporated
herein by
reference to
Exhibit 10.4.1 of
the registration
statement on
Form S-1 of
Algos
Pharmaceutical
Corporation
declared effective
on September 25,
1996)10.38
[Intentionally
Omitted.]10.39
Master
Development and
Toll
Manufacturing
Agreement, dated
as of May 3,
2001, by and
between Novartis
Consumer
Health, Inc. and
Endo
Pharmaceuticals
(incorporated
herein by
reference to
Exhibit 10.39 of
the Form 10-Q
for the Quarter
Ended June 30,
2001 filed with
the Commission
on August 14,

Table of Contents

Exhibit No.	Title
2001)10.40 [Intentionally Omitted.]10.41 Service Agreement, dated as of February 1, 2001, by and between Endo Pharmaceuticals and Ventiv Health U.S. Sales Inc. (incorporated herein by reference to Exhibit 10.41 of the Current Report on Form 8-K dated August 31, 2001)11 Statement Regarding Computation of per Share Earnings99.1 Certificate of the Chairman and Chief Executive Officer of Endo pursuant to Section 906 of the Sarbanes-Oxley Act of 200299.2 Certificate of the Chief Financial Officer of Endo pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	

* A management contract or compensatory plan or arrangement required to be filed as an Exhibit pursuant to Item 14(c) of Form 10-K.